API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Lutris Pharma

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop L...

Details:

The award will allow for the completion of Investigational New Drug enabling studies. Specifically, the funds will be utilized for the manufacturing of LUT017 active pharmaceutical ingredient and the final formulated drug product (LUT017 gel) to supply the proposed studies.

Lead Product(s): LUT017

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: LUT017

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: California Institute of Regenerative Medicine

Deal Size: $5.0 million Upfront Cash: Undisclosed

Deal Type: Funding October 24, 2022

ASK
US